Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$128.77 USD
+1.38 (1.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $128.69 -0.08 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
SRPT 128.77 +1.38(1.08%)
Will SRPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for SRPT
Optimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label Expansion
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Edgewise gets EU orphan drug status for muscular dystrophy drug
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
As more rare disease therapies launch, their prices are rising